Anti-AIDS agents 81. design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 8, 2010, Pages 3133-3141

  Qian, Keduo ^a   Kuo, Reen Yun ^a   Chen, Chin Ho ^b   Huang, Li ^b   Morris Natschke, Susan L ^a   Lee, Kuo Hsiung ^a  

^a University of North Carolina   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA O (3' ETHYLMETHYLSUCCINYL)BETULINIC ACID; ANTIRETROVIRUS AGENT; BETULIC ACID; BETULINIC ACID DERIVATIVE; BEVIRIMAT; MORONIC ACID DERIVATIVE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHARMACOPHORE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; HIV-1; MUTATION; OLEANOLIC ACID; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRITERPENES; VIRION; VIRUS REPLICATION;

EID: 77951105934     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901782m     Document Type: Article

References (23)

1. UNAIDS. AIDS Epidemic Update; November, 2009.
2. Kawalekar, O. U.; Shedlock, D. J.; Weiner, D. B. Current strategies and limitations of HIV vaccines Curr. Opin. Invest. Drugs 2010, 11, 192-202
3. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 1995, 373, 123-126
4. Hammer, S. M.; Katzenstein, D. A.; Hughes, M. D.; Gundacker, H.; Schooley, R. T.; Haubrich, R. H.; Henry, W. K.; Lederman, M. M.; Phair, J. P.; Niu, M.; Hirsch, M. S.; Merigan, T. C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team N. Engl. J. Med. 1996, 335, 1081-1090
5. Piscitelli, S. C.; Flexner, C.; Minor, J. R.; Polis, M. A.; Masur, H. Drug interactions in patients infected with human immunodeficiency virus Clin. Infect. Dis. 1996, 23, 685-693
6. Boden, D.; Hurley, A.; Zhang, L.; Cao, Y.; Guo, Y.; Jones, E.; Tsay, J.; Ip, J.; Farthing, C.; Limoli, K.; Parkin, N.; Markowitz, M. HIV-1 drug resistance in newly infected individuals JAMA, J. Am. Med. Assoc. 1999, 282, 1135-1141
7. Pereira, C. F.; Paridaen, J. T. Anti-HIV drug development - an overview Curr. Pharm. Des. 2004, 10, 4005-4037
8. Wegner, S. A.; Brodine, S. K.; Mascola, J. R.; Tasker, S. A.; Shaffer, R. A.; Starkey, M. J.; Barile, A.; Martin, G. J.; Aronson, N.; Emmons, W. W.; Stephan, K.; Bloor, S.; Vingerhoets, J.; Hertogs, K.; Larder, B. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel AIDS 2000, 14, 1009-1015
9. Kashiwada, Y.; Hashimoto, F.; Cosentino, L. M.; Chen, C. H.; Garrett, P. E.; Lee, K. H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents J. Med. Chem. 1996, 39, 1016-1017
10. Li, F.; Goila-Gaur, R.; Salzwedel, K.; Kilgore, N. R.; Reddick, M.; Matallana, C.; Castillo, A.; Zoumplis, D.; Martin, D. E.; Orenstein, J. M.; Allaway, G. P.; Freed, E. O.; Wild, C. T. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13555-13560
11. Kanamoto, T.; Kashiwada, Y.; Kanbara, K.; Gotoh, K.; Yoshimori, M.; Goto, T.; Sano, K.; Nakashima, H. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation Antimicrob. Agents Chemother. 2001, 45, 1225-1230
12. Smith, P. F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G. P.; Martin, D. E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3- o -(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection Antimicrob. Agents Chemother. 2007, 51, 3574-3581
13. Martin, D. E.; Blum, R.; Doto, J.; Galbraith, H.; Ballow, C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers Clin. Pharmacokinet. 2007, 46, 589-598 (Pubitemid 47025359)
14. Martin, D. E.; Blum, R.; Wilton, J.; Doto, J.; Galbraith, H.; Burgess, G. L.; Smith, P. C.; Ballow, C. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers Antimicrob. Agents Chemother. 2007, 51, 3063-3066
15. Yu, D.; Wild, C. T.; Martin, D. E.; Morris-Natschke, S. L.; Chen, C. H.; Allaway, G. P.; Lee, K. H. The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV Expert Opin. Invest. Drugs 2005, 14, 681-693
16. Ito, J.; Chang, F. R.; Wang, H. K.; Park, Y. K.; Ikegaki, M.; Kilgore, N.; Lee, K. H. Anti-AIDS agents 48. Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis J. Nat. Prod. 2001, 64, 1278-1281
17. Qian, K.; Nakagawa-Goto, K.; Yu, D.; Morris-Natschke, S. L.; Nitz, T. J.; Kilgore, N.; Allaway, G. P.; Lee, K. H. Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3- O -monomethylsuccinyl- betulinic acid derivatives Bioorg. Med. Chem. Lett. 2007, 17, 6553-6557
18. Keyling-Bilger, F.; Schmitt, G.; Beck, A.; Luu, B. Synthesis of optically active diastereomers of a nonproteic neurotrophic mimetic Tetrahedron 1996, 52, 14891-14904
19. Kawasaki, M.; Shinada, T.; Hamada, M.; Ohfune, Y. Total synthesis of (-)-kaitocephalin Org. Lett. 2005, 7, 4165-4167
20. Roehm, N. W.; Rodgers, G. H.; Hatfield, S. M.; Glasebrook, A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT J. Immunol. Methods 1991, 142, 257-265
21. Qian, K.; Yu, D.; Chen, C. H.; Huang, L.; Morris-Natschke, S. L.; Nitz, T. J.; Salzwedel, K.; Reddick, M.; Allaway, G. P.; Lee, K. H. Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents J. Med. Chem. 2009, 52, 3248-3258
22. Demirov, D. G.; Ono, A.; Orenstein, J. M.; Freed, E. O. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function Proc. Natl. Acad. Sci. U.S.A 2002, 99, 955-960
23. Kiernan, R. E.; Ono, A.; Englund, G.; Freed, E. O. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle J. Virol. 1998, 72, 4116-4126